The U.S. Food and Drug Administration issued an emergency use authorization or EUA for the COVID-19 Self-Collected Antibody Test System developed by Symbiotica, Inc.
It is the first antibody test authorized for use with home collected dried blood spot samples. The collected samples will be sent to a Symbiotica laboratory for analysis.
A COVID-19 antibody test, also known as a serology test, is a blood test that can detect if a person has antibodies to SARS-CoV-2, the virus that causes COVID-19. The test helps identify people who may have had a prior infection or who may have recovered from COVID-19.
However, the antibody tests cannot detect the presence of the SARS-CoV-2 virus to diagnose COVID-19.
Symbiotica's COVID-19 Self-Collected Antibody Test System is authorized for prescription use with a fingerstick dried blood sample that is self-collected by an individual age 18 years or older or collected by an adult from an individual 5 years of age and older.
Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, said, "The authorization of the first prescription use, home collection antibody test will play an important role in helping health care professionals identify individuals who have developed an adaptive immune response from a recent or prior COVID-19 infection."
Many antibody tests are currently in development stage or available for use to detect antibodies to SARS-CoV-2.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.